Aptevo Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APVO research report →
Price Chart
About the company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
- CEO
- Jeffrey G. Lamothe
- IPO
- 2016
- Employees
- 33
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on APVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.93M
- P/E
- -0.01
- Fwd P/E
- 0.18
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.36
- EV/EBITDA
- -0.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -201.49%
- ROIC
- -262.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-240,000+31.8%
- Op Income
- $-26,312,000
- Net Income
- $-25,967,000-7.6%
- EPS
- $-87.27+99.7%
- OCF Growth
- -7.6%
- FCF Growth
- -7.6%
- 52W High
- $33.12
- 52W Low
- $1.37
- 50D MA
- $2.65
- 200D MA
- $5.37
- Beta
- 1.68
- RSI (14)
- 35
- Avg Volume
- 113.40K
No earnings-call transcripts are available for APVO yet.
- Free Float
- 92.0%
- Shares Outstanding
- 1.25M
- Float Shares
- 1.15M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for APVO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Stephen CohenHouse · TN09 | Sell | Jun 24, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gsa Capital Partners Llp | 21.54K | ▲ 1.90K |
| Vanguard Group Inc | 16.86K | ▲ 16.86K |
| Vanguard Capital Management LLC | 12.71K | 0 |
| Geode Capital Management, LLC | 10.82K | ▼ 2.52K |
| Vanguard Fiduciary Trust Co | 4.14K | 0 |
| Ubs Group AG | 730 | ▼ 2.71K |
| Advisor Group Holdings, Inc. | 360 | 0 |
| Sbi Securities Co., Ltd. | 109 | 0 |
| Barclays PLC | 31 | ▲ 31 |
| Cwm, LLC | 5 | ▲ 5 |
| Danske Bank A/S | 1 | 0 |
Held by 5 ETFs
Biggest fund positions in APVO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 6, 26 | Harsanyi Zsolt | other | 400 |
| Aug 6, 26 | Harsanyi Zsolt | other | 400 |
| Aug 6, 26 | Lamothe Jeffrey G. | other | 961 |
| Aug 6, 26 | Lamothe Jeffrey G. | other | 961 |
| Aug 6, 26 | Taylor Daphne | other | 638 |
| Aug 6, 26 | Taylor Daphne | other | 638 |
| Aug 6, 26 | Kwon SoYoung | other | 638 |
| Aug 6, 26 | Kwon SoYoung | other | 638 |
| Aug 6, 26 | Huebner Dirk | other | 638 |
| Aug 6, 26 | Huebner Dirk | other | 156 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APVO coverage
Recent articles, reports, and earnings notes.
No research on APVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APVO report →Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Rises 59.0%
defenseworld.net · Oct 1
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
accessnewswire.com · Sep 24
Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average – Should You Sell?
defenseworld.net · Sep 18
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
benzinga.com · Sep 3
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
accessnewswire.com · Sep 3
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
accessnewswire.com · Aug 14
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
accessnewswire.com · Aug 13
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
accessnewswire.com · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.